- Home
- ZG vs BIIB Comparison
ZG vs BIIB Comparison
Compare ZG & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZG
- BIIB
- Stock Information
- Founded
- ZG 2004
- BIIB 1978
- Country
- ZG United States
- BIIB United States
- Employees
- ZG N/A
- BIIB N/A
- Industry
- ZG Business Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ZG Consumer Discretionary
- BIIB Health Care
- Exchange
- ZG Nasdaq
- BIIB Nasdaq
- Market Cap
- ZG 17.6B
- BIIB 19.9B
- IPO Year
- ZG 2011
- BIIB 1991
- Fundamental
- Price
- ZG $66.17
- BIIB $131.20
- Analyst Decision
- ZG Buy
- BIIB Buy
- Analyst Count
- ZG 27
- BIIB 26
- Target Price
- ZG $81.32
- BIIB $194.95
- AVG Volume (30 Days)
- ZG 572.3K
- BIIB 1.7M
- Earning Date
- ZG 05-07-2025
- BIIB 05-01-2025
- Dividend Yield
- ZG N/A
- BIIB N/A
- EPS Growth
- ZG N/A
- BIIB 26.39
- EPS
- ZG N/A
- BIIB 10.12
- Revenue
- ZG $2,305,000,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- ZG $16.68
- BIIB N/A
- Revenue Next Year
- ZG $14.99
- BIIB N/A
- P/E Ratio
- ZG N/A
- BIIB $12.83
- Revenue Growth
- ZG 14.96
- BIIB 1.59
- 52 Week Low
- ZG $38.57
- BIIB $110.04
- 52 Week High
- ZG $86.58
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- ZG 50.01
- BIIB 59.82
- Support Level
- ZG $63.25
- BIIB $123.97
- Resistance Level
- ZG $67.05
- BIIB $132.94
- Average True Range (ATR)
- ZG 1.61
- BIIB 3.49
- MACD
- ZG -0.12
- BIIB 1.04
- Stochastic Oscillator
- ZG 39.30
- BIIB 88.37
About ZG Zillow Group Inc.
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Premier Agent and others.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.